Citations

Clear

1053 citation(s) found for "Andre, F".

Evaluation of a retinal deep phenotyping platform to detect the likely cerebral amyloid PET status in humans
Soucy, Jean‐Paul , Chevrefils, Claudia, Osseiran, Sam , Sylvestre, Jean‐Philippe, Beaulieu, Sylvain, Arbour, Jean Daniel, Rhéaume, Marc‐André , Villeneuve, Sylvia , Nasreddine, Ziad, Gauthier, Serge , Robillard, Alain, Chayer, Céline, Shahawy, Hossam El, Chen, John J. , Lowe, Val J. , Pascoal, Tharick Ali , Rosa-Neto, Pedro , Black, Sandra E. , Kertes, Peter J. , Knopman, David S. , Lesage, Frédéric

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.043395 Get It

AbstractBackgroundTranslating recent advances in the diagnosis of Alzheimer’s disease (AD) and other dementias to clinical practice using biomarker‐based approaches requires accessible, affordable biomarkers. This protocol tested the performance of a Retinal Deep Phenotyping platform for the detection of likely positron‐emission tomography (PET) amyloid status (negative or positive) in human subjects. This platform generates data rich retinal reflectance images captured non‐invasively with a Metabolic Hyperspectral Retinal Camera (MHRC) yielding specific spatial‐spectral features which are analyzed by a machine learning algorithm relatively to a recognized gold standard biomarker (in this case PET amyloid imaging).Methods134 subjects (50 years and older) from 3 clinical sites were included, 94 with normal, 40 with abnormal cognition, imaged with the MHRC and amyloid PET (unanimous visual reads from a panel of 3 expert reviewers; 42 amyloid positive, 92 negative). Over 600 spatial‐spectral features were extracted from hyperspectral retinal images obtained at 450‐900 nm. After a feature selection based on F‐score ranking, a classifier was trained on the datasets from 87 patients (2/3 of the cohort) using the most discriminating features. The classification performance was then evaluated with the datasets from the remaining 47 patients.ResultsResubstituting the training set of 87 patients into the classifier yielded sensitivity and specificity values of 88% and 91%, respectively. The training misclassification rate was predicted using the k‐fold loss metric, with a predicted error rate of 19%. To verify this performance, the test set of 47 patients was classified by the model resulting in sensitivity and specificity values of 80% and 81%, respectively.ConclusionsThe Retinal Deep Phenotyping platform shows promise for detecting the likely cerebral amyloid PET status in human subjects and could serve as a screening tool to identify subjects in the AD continuum, for instance in a clinical or drug development context. The platform could also be used for the detection of other biomarkers involved in cognitive decline.
Hearing loss and microstructural integrity of the brain in a dementia‐free older population
Croll, Pauline H. , Goedegebure, André , Rigters, Stephanie C. , Sharrett, A. Richey , Lin, Frank R. , Vernooij, Meike W. , Reid, Robert I. , Power, Melinda C. , Jong, Robert J. Baatenburg de , Mosley, Thomas H. , Groot, Marius de , Deal, Jennifer A.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S10 | Pages: No page available

10.1002/alz.042878 Get It

AbstractBackgroundRecently, hearing loss has been identified as a promising modifiable risk factor for dementia. Several hypotheses explaining a potential underlying pathway have been proposed, including the sensory deprivation hypothesis, describing a direct causal relationship in which hearing loss leads to neuroplastic changes in the brain. Indeed, hearing loss has been associated with smaller macrostructural brain volumes, which is believed to at least partly explain the association between hearing loss and neurodegenerative disease. However, microstructural changes precede macrostructural changes. Therefore, we aimed to assess the association between hearing loss and microstructural integrity of the brain.Methods1,086 dementia‐free older adults from the Atherosclerosis Risk in Communities (ARIC) study (mean age = 75.2 [SD: 4.9], 61.4% female) underwent hearing assessment (2016‐2017) and magnetic resonance imaging (MRI) of the brain (2011‐2013). Hearing was assessed with pure‐tone audiometry. Microstructural integrity (fractional anisotropy (FA) and mean diffusivity (MD)) of multiple brain regions was determined with diffusion tensor imaging (DTI). Multivariable linear regression models were used to investigate the association between hearing loss and microstructural integrity of the lobes, temporal lobe gyri, medial temporal lobe structures and white matter (WM) tracts, adjusting for relevant confounders.ResultHearing loss was associated with lower WM microstructural integrity in the temporal lobe (difference in SD FA for moderate/severe hearing loss as compared to normal hearing: ‐0.19 [95% CI: ‐0.35, ‐0.03]; and difference in SD MD for moderate/severe hearing loss as compared to normal hearing: 0.15 [95% CI: 0.01, 0.28]). Hearing loss was associated with lower gray matter (GM) microstructure of the hippocampus, but not the amygdala. Moreover, hearing loss was associated with lower WM microstructural integrity of the limbic tracts and the uncinate fasciculus (Figure 1).ConclusionOur results demonstrate that age‐related hearing loss is associated with lower WM microstructural integrity in the temporal lobe, the limbic tracts and the uncinate fasciculus and lower GM microstructure in the hippocampus. These associations suggest that poorer hearing may affect brain regions that are important for different cognitive processes. However, the results should be interpreted with caution as this study is of a cross‐sectional design.
Pitfalls in Identification of Methicillin-Resistant Staphylococcus aureus
Marcoux, J. André, Washington, John A.

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 18 | Issue: 4 | Pages: 699-700

10.1128/am.18.4.699-700.1969 | PMID 5197918 Get It

Media and techniques for in vitro testing with respect to screening for methicillin-resistant Staphylococcus aureus are discussed.
CSIG-08. TARGETING ION TRANSPORT-REGULATORY KINASES AS A NOVEL TREATMENT FOR GLIOBLASTOMA
Meade, Paola Suarez, Miranda-Herrera, Pierre A., Bechtle, Alexandra , Issacs, Farren, Quiñones‐Hinojosa, Alfredo , Schiapparelli, Paula , Levchenko, Andre , Rinehart, Jesse

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii29-ii29

10.1093/neuonc/noaa215.120 Get It

Abstract Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Currently, treatment is focused on achieving maximal safe resection, followed by chemo- and radiotherapy. Although surgery remains the most important therapeutic component, complete surgical resection is virtually impossible, as GBM cells readily infiltrate the adjacent brain parenchyma. One fundamental mechanism for GBM cell migration is the ability of these cells to use cell volume regulation as a driving force of cell infiltration and potentially interfering with apoptosis and cell cycle progression. In this work, we targeted the master regulators of cell volume, the kinases STE20/SPS1-Related Proline-Alanine-Rich Protein Kinase (SPAK) and Oxidative stress-responsive kinase-1) (OSR1) by using a novel proprietary small molecule inhibitor. In order to study the effects of inhibiting SPAK and OSR1, we analyzed cell proliferation and migration. First, we determined the IC50 using six different patient-derived GBM cell lines; we found IC50 values ranging from 0.2–2μM. Next, cell proliferation was determined by cell cycle analysis through Edu labeling. We found a significant decrease in S phase and cell cycle arrest in G2M (p= 0.001, n=6). In addition, cell migration was determined using boyden chamber assay. We found a dose-dependent reduction in cell migration (p=0.001, n=3). These results correlated with the phenomenon observed in an orthotopic murine model of GBM, in which the inhibitor showed a decrease in tumor growth (p=0.0026, n=4) and greater survival rates in vivo (p=0.0046, n=8). When used in combination with radiation therapy, this small molecule inhibitor was capable of radio-sensitizing GBM cells decreasing clonogenicity (p=0.01, n=3) were observed in vitro. In summary, by targeting the SPAK/OSR1 kinases with a small molecule inhibitor, GBM cells become less aggressive, mainly by interfering with cell migration and proliferation and becoming more sensitive to radiation.
Regenerative Outlook: Offering Global Solutions for Equitable Care
Leask, Freya , Terzic, André , Terzic, Andre

Mayo Clinic

Regenerative Medicine | November 27, 2020 | Volume: 15 | Issue: 11 | Pages: 2249-2252

10.2217/rme-2020-0177 | PMID 33245010 Get It

Combination of BMP2 and EZH2 Inhibition to Stimulate Osteogenesis in a 3D Bone Reconstruction Model
Lui, Hayman , Vaquette, Cedryck , Denbeigh, Janet M. , Cool, Simon M. , Dudakovic, Amel , Wijnen, André J. van , Samsonraj, Rebekah M. , Denbeigh, Janet, van Wijnen, Andre J , Vaquette, Cédryck , Kakar, Sanjeev

Mayo Clinic

Tissue Engineering Part A | November 25, 2020 | Volume: 27 | Issue: 15-16 | Pages: 1084-1098

10.1089/ten.tea.2020.0218 | PMID 33234056 Get It

High concentrations of bone morphogenetic protein 2 (BMP2) in bone regeneration cause adverse events (e.g, heterotopic bone formation and acute inflammation). This study examines novel epigenetic strategies (i.e., EZH2 inhibition) for augmenting osteogenesis, thereby aiming to reduce the required BMP2 dose in vivo for bone regeneration and minimize these adverse effects. Human bone marrow-derived mesenchymal stem cells (BMSCs) were grown on three-dimensional (3D)-printed medical-grade polycaprolactone scaffolds and incubated in osteogenic media containing 50 ng/mL BMP2 and/or 5 μM GSK126 (EZH2 inhibitor) for 6 days ( n = 3 per group and timepoint). Constructs were harvested for realtime quantitative polymerase chain reaction analysis at Day 10 and immunofluorescence (IF) microscopy at Day 21. After pretreating for 6 days and maintaining in osteogenic media for 4 days, BMSC-seeded scaffolds were also implanted in an immunocompromised subcutaneous murine model ( n = 39; 3/group/donor and 3 control scaffolds) for histological analysis at 8 weeks. Pretreatment of BMSCs with BMP2 and BMP2/GSK126 costimulated expression of osteoblast-related genes (e.g., IBSP , SP7 , RUNX2 , and DLX5 ), as well as protein accumulation (e.g., collagen type 1/ COL1A1 and osteocalcin/ BGLAP ) based on IF staining. While in vivo implantation for 8 weeks did not result in bone formation, increased angiogenesis was observed in BMP2 and BMP2/GSK126 groups. This study finds that BMP2 and GSK126 costimulate osteogenic differentiation of MSCs on 3D scaffolds in vitro and may contribute to enhanced vascularization when implanted in vivo to support bone formation. Thus, epigenetic priming with EZH2 inhibitors may have translational potential in bone healing by permitting a reduction of BMP2 dosing in vivo to mitigate its side effects. Impact statement While autografts are still the gold standard for bone reconstruction, tissue availability and donor morbidity are significant limitations. Previous attempts to use high concentrations of bone morphogenetic protein 2 (BMP2) have been shown to cause adverse events such as excessive bone formation and acute inflammation. Overall, the utilization of EZH2 inhibitors to modulate gene expression in favor of bone healing has been demonstrated in vitro in a tissue engineering strategy. Our study will pave the way to developing tissue engineering strategies involving GSK126 as an adjuvant to increase the effects of BMP2 for stimulating cells of interest on a three-dimensional scaffold for bone regeneration.
From dermatological conditions toCOVID‐19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy
Criado, Paulo Ricardo , Miot, Hélio Amante , Pincelli, Thaís , Fabro, Alexandre Todorovic , Pincelli, Thais Prota Hussein, Pincelli, T , Criado, P R , Fabro, Alexandre Todorovic

Mayo Clinic

Dermatologic Therapy | November 21, 2020 | Volume: 34 | Issue: 1 | Pages: No page available

10.1111/dth.14565 | PMID 33219572 Get It

Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype
Dudakovic, Amel , Khatib, Casper M. , Farrell, Mariah , Costa, Samantha , Falank, Carolyne , Hinge, Maja , Murphy, Connor , DeMambro, Victoria , Pettitt, Jessica A. , Lary, Christine W. , McDonald, Michelle M. , Wijnen, André J. van , Jafari, Abbas , Reagan, Michaela R. , Khatib, Casper M , Falank, Carolyne , Murphy, Connor S , Driscoll, Heather E , McDonald, Michelle M , Kassem, Moustapha , Reagan, Michaela R , van Wijnen, Andre J , Fairfield, Heather E. , Kassem, Moustapha , Rosen, Clifford J. , Andersen, Thomas Lund

Mayo Clinic

Cancer Research | November 20, 2020 | Volume: 81 | Issue: 3 | Pages: 634-647

10.1158/0008-5472.can-20-1088 | PMID 33218968 Get It

Abstract Bone marrow adipocytes (BMAd) have recently been implicated in accelerating bone metastatic cancers, such as acute myelogenous leukemia and breast cancer. Importantly, bone marrow adipose tissue (BMAT) expands with aging and obesity, two key risk factors in multiple myeloma disease prevalence, suggesting that BMAds may influence and be influenced by myeloma cells in the marrow. Here, we provide evidence that reciprocal interactions and cross-regulation of myeloma cells and BMAds play a role in multiple myeloma pathogenesis and treatment response. Bone marrow biopsies from patients with multiple myeloma revealed significant loss of BMAT with myeloma cell infiltration of the marrow, whereas BMAT was restored after treatment for multiple myeloma. Myeloma cells reduced BMAT in different preclinical murine models of multiple myeloma and in vitro using myeloma cell-adipocyte cocultures. In addition, multiple myeloma cells altered adipocyte gene expression and cytokine secretory profiles, which were also associated with bioenergetic changes and induction of a senescent-like phenotype. In vivo, senescence markers were also increased in the bone marrow of tumor-burdened mice. BMAds, in turn, provided resistance to dexamethasone-induced cell-cycle arrest and apoptosis, illuminating a new possible driver of myeloma cell evolution in a drug-resistant clone. Our findings reveal that bidirectional interactions between BMAds and myeloma cells have significant implications for the pathogenesis and treatment of multiple myeloma. Targeting senescence in the BMAd or other bone marrow cells may represent a novel therapeutic approach for treatment of multiple myeloma. Significance: This study changes the foundational understanding of how cancer cells hijack the bone marrow microenvironment and demonstrates that tumor cells induce senescence and metabolic changes in adipocytes, potentially driving new therapeutic directions.
Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Isganaitis, Elvira , Raghinaru, Dan, Ambler-Osborn, Louise, Pinsker, Jordan E. , Buckingham, Bruce A. , Ekhlaspour, Laya , Kudva, Yogish C., Forlenza, Gregory P. , Beck, Roy W., Kollman, Craig, Lum, John W. , Brown, Sue A. , Laffel, Lori M. , Kovatchev, Boris, Anderson, Stacey, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari, Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Laffel, Lori, Pinsker, Jordan, Doyle, Francis, Renard, Eric, Reznik, Yves , Lum, John, Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Green, Jennifer , Legault, Laurent , Wysham, Carol , Eggerman, Thomas, Forlenza, Gregory P , Buckingham, Bruce , Wadwa, R Paul , Kudva, Yogish C. , Levy, Carol J. , Kollman, Craig , Kovatchev, Boris , Anderson, Stacey M. , Oliveri, Mary Clancy , Kumari, Kanchan , Messer, Laurel H , Jacobson, Tali, Doyle, Francis J. , Patibandla, Nandan, Laffel, Lori M. , Cobelli, Claudio , Beck, Roy W. , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | November 20, 2020 | Volume: 23 | Issue: 5 | Pages: 342-349

10.1089/dia.2020.0572 | PMID 33216667 Get It

Objective: To assess the efficacy and safety of closed-loop control (CLC) insulin delivery system in adolescents and young adults with type 1 diabetes. Research Design and Methods: Prespecified subanalysis of outcomes in adolescents and young adults aged 14–24 years old with type 1 diabetes in a previously published 6-month multicenter randomized trial. Participants were randomly assigned 2:1 to CLC (Tandem Control-IQ) or sensor augmented pump (SAP, various pumps+Dexcom G6 CGM) and followed for 6 months. Results: Mean age of the 63 participants was 17 years, median type 1 diabetes duration was 7 years, and mean baseline HbA1c was 8.1%. All 63 completed the trial. Time in range (TIR) increased by 13% with CLC versus decreasing by 1% with SAP (adjusted treatment group difference = +13% [+3.1 h/day]; 95% confidence interval [CI] 9–16, P < 0.001), which largely reflected a reduction in time >180 mg/dL (adjusted difference −12% [−2.9 h/day], P < 0.001). Time <70 mg/dL decreased by 1.6% with CLC versus 0.3% with SAP (adjusted difference −0.7% [−10 min/day], 95% CI −1.0% to −0.2%, P = 0.002). CLC use averaged 89% of the time for 6 months. The mean adjusted difference in HbA1c after 6 months was 0.30% in CLC versus SAP (95% CI −0.67 to +0.08, P = 0.13). There was one diabetic ketoacidosis episode in the CLC group. Conclusions: CLC use for 6 months was substantial and associated with improved TIR and reduced hypoglycemia in adolescents and young adults with type 1 diabetes. Thus, CLC has the potential to improve glycemic outcomes in this challenging age group. The clinical trial was registered with ClinicalTrials.gov (NCT03563313).
Method Limitations in LC-MS/MS and Immunonephelometric Measurement of IgG Subclasses
Gugten, Grace van der, Mattman, André , Ritchie, Gordon , Chen, Luke Y. C. , Chin, Alex , Mills, John R. , Rao, Lokinendi V. , Holmes, Daniel T.

Mayo Clinic

Clinical Chemistry | November 18, 2020 | Volume: 67 | Issue: 2 | Pages: 440-441

10.1093/clinchem/hvaa303 | PMID 33331942 Get It